Oncotelic granted Lunai Bioworks worldwide rights to its nose-to-brain delivery system for biodefense and Alzheimer's. Nearly 98% of small-molecule drugs fail to cross the blood-brain barrier.
An ultrasensitive test detects TDP-43 seeds in CSF to diagnose FTLD-TDP. At-home blood tests show promise for remote dementia triage, but primary care use of plasma biomarkers remains limited.
Alzheimer's blood tests are gaining FDA clearances and strong patient interest, yet surveys show clinicians remain skeptical about their reliability and clinical benefit. A UK survey found fewer than one-third of psychiatrists have used biomarkers, while only 6% of memory services meet access guidelines. An ethical framework urges careful implementation, especially in primary care.
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
Researchers at Washington University School of Medicine developed a blood test-based method to predict when Alzheimer's symptoms will begin, with accuracy within three to four years, using plasma p-tau217 protein levels.
A single blood test measuring p-tau217 protein can predict when cognitively unimpaired individuals will develop Alzheimer's symptoms, with a margin of error of 3-4 years, potentially accelerating clinical trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07431528 |
Dementia and Storytelling in Vietnam |
NOT_YET_RECRUITING | NA |
| NCT07378800 |
Fostering Positive Care Interactions in Assisted Living |
ACTIVE_NOT_RECRUITING | NA |
| NCT07180719 |
Effectiveness of a Dementia Anti-Stigma Intervention in Rural Kenya |
NOT_YET_RECRUITING | NA |
| NCT07032350 |
E-Tailored Pain Management Support for Dementia Family Caregivers: Feasibility of the PACE-app |
RECRUITING | NA |
| NCT06856681 |
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease |
WITHDRAWN | NA |
| NCT06825403 |
Olfactory Training in Mild Cognitive Impairment |
RECRUITING | NA |
| NCT06801639 |
Advancing Alzheimer's Care: Home-based tDCS for Affective Symptoms |
RECRUITING | NA |
| NCT06733714 |
Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults |
RECRUITING | NA |
| NCT06647498 |
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation |
RECRUITING | PHASE2/PHASE3 |
| NCT06582706 |
Nicotinic Acid for the Treatment of Alzheimer's Disease |
RECRUITING | PHASE1/PHASE2 |
